End of down trend?I see a hammer candle with it coming close to end of the trend line, which way will she go? I think to the upside since the candle! Let's go! Low float and lots of gap fills to upside still remain!
PULM trade ideas
Bullish trend after a Bear attackMy partner and I predict this stock is going to spike exponentially by Friday next week.
$PULM Pattern moving #PULMVolume will continue to drive momentum or pullback to support before taking off!
PULM 1W Swing Editiontest
Pulmatrix, Inc. is a clinical stage biotechnology company, which engages in the discovery and development of novel inhaled therapeutic products for respiratory and other diseases. The firm focuses on the prevention and treatment of respiratory diseases and infections. It offers products based on its proprietary dry powder delivery technology, iSPERSE, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. The company was founded by David Alan Edwards, Mark J. Gabrielson, Alexander M. Klibanov, and Robert S. Langer, Jr. on June 15, 2015 and is headquartered in Lexington, MA.
PULM ASCENDING TRIANGLE?!An ascending triangle has a horizontal resistance line and usually occurs as a continuation of a bullish trend. Don't enter now. Overall trend is still downwards!
Chart structure on this looks fantastic. BIG OPP HERELooks to be close to bottom of descending and around the 2019 long term support. Clear skies above and this could realistically be a 10 bagger from here
Short Swing - 30min TFPrice finding solid support around 1.30. Traveling just below 50MA. Should make a move up towards 200MA and potential gap fill at 1.50+
PULM Inverted head and shoulders Pulmatrix Inc. is a clinical stage biotechnology company, which engages in the discovery and development of novel inhaled therapeutic products for respiratory and other diseases. The firm focuses on the prevention and treatment of respiratory diseases and infections. It offers products based on its proprietary dry powder delivery technology, iSPERSE, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications.
Looking for breakout of blue line . This could be a major player in administering any medicine that needs to get to the lungs. Awfully quiet right now...could change soon.
PULM : A breath of fresh OpportunityThis drug company with lung inhaler administered medicine appears to have bottomed and is moving some. Being bought by Armistice Hedge fund. I can wait. Targets will provide 3x and 10x approx.
Pulmatrix Inc moving premarket
Looking for continuation and possible breakout today in PULM
Pulmatrix, Inc. is a clinical stage biotechnology company, which engages in the discovery and development of novel inhaled therapeutic products for respiratory and other diseases. The firm focuses on the prevention and treatment of respiratory diseases and infections. It offers products based on its proprietary dry powder delivery technology, iSPERSE, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. The company was founded by David Alan Edwards, Mark J. Gabrielson, Alexander M. Klibanov, and Robert S. Langer, Jr. on June 15, 2015 and is headquartered in Lexington, MA.
Pulmatrix Inc On breakout watch
Alert set for break above $1.90 for potential breakout
Strong RSi and MACD
Pulmatrix, Inc On alert for week ahead $pulmPulmatrix, Inc. is a clinical stage biotechnology company, which engages in the discovery and development of novel inhaled therapeutic products for respiratory and other diseases. The firm focuses on the prevention and treatment of respiratory diseases and infections. It offers products based on its proprietary dry powder delivery technology, iSPERSE, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. The company was founded by David Alan Edwards, Mark J. Gabrielson, Alexander M. Klibanov, and Robert S. Langer, Jr. on June 15, 2015 and is headquartered in Lexington, MA.
Potential Short Position - 4h Interval - PULMHello Everyone,
The stock (PULM) experienced rapid growth (bull) within today's market. Considering the current sporadic momentum upwards, there is none-the-less an opportunity to short the stock till price consolidation.
Resistance Level 1 - (4.30 - 4.50) 20 pip interval
Blue Horizontal Line - (1.80 - 2.10) 30 pip interval
Support Level 1 - (0.50 - 0.80) 30 pip interval
Furthermore, (PULM)'s Net Income: -18.056M which can be quite alarming, as their return on assets is negative as well (-1.1653). If they can revitalize the negative totals (into positive), there still may be hope for them in the coming months and year.
Not Investment Advice. For Educational and Analytical Purposes Only. (Be Aware and Stick To Your Trading Itinerary)***
-LionGate
Pulmatrix Drug Candidate Receives QIDP Designation from the FDAPulmatrix Drug Candidate Receives "Qualified Infectious Disease Product" (QIDP) Designation from the FDA
The FDA designation adds five years of market exclusivity for Pulmatrix' inhaled product for treating fungal infections in the lungs of CF patients
Under the QIDP program, which is designed to speed the development of novel drugs against important pathogens, Pulmatrix will receive five years of additional market exclusivity for PUR1900.
the FDA wrote: "We have reviewed your request and conclude that it meets the criteria for QIDP. Therefore we are designating your Itraconazole Inhalation Powder (PUR1900) product for inhalation use as a QIDP for….treatment of pulmonary Aspergillus infections in patients with cystic fibrosis."
"The new QIDP designation is a significant boost to our efforts to make this drug available as quickly as possible to cystic fibrosis (CF) patients suffering from fungal lung infections.
"It will give us the benefit of an expedited regulatory review.
Added to our existing FDA Orphan drug designation for PUR1900, it will give us a full 12 years of market exclusivity."
"By delivering the drug directly to the lungs, we should be able to fight the infection far more effectively than the oral drug can, with far fewer side effects,"
ir.pulmatrix.com
PULM rising wave structure...PULM rising wave structure. The exchange rate may be at the beginning of a triple ascending wave structure. The rising wave axis (green line) and the rising ATR axis also assume that the rising rise can be definite and dynamic. The exchange rate is supported by a D1 ATR axis. The target price of the third rising wave structure may be 2.5 usd.
PULM Short Term BullishPULM is setting up for a good short term swing. Long term might be a little risky since SEC PRE-14A will have a June 2018 vote for a RSI proxy vote.
